(Adnkronos) - La conferenza stampa organizzata da Lilly a Milano ed intitolata “Dermatite atopica ed alopecia areata, due patologie, un solo farmaco. Via libera alla rimborsabilità”, è stata l’occasione per ribadire l’importanza di avere finalmente a disposizione un farmaco innovativo, efficace, sicuro e rimborsabile come Baricitinib. Le due patologie a cui è stato dedicato l'incontro, hanno un impatto profondo sulla qualità della vita dei pazienti, che tocca tanto la sfera emotiva quanto quella fisica.
Category
🗞
NewsTranscript
00:00 It is also worth mentioning the aesthetic side, the impact of atopic dermatitis and alopecia
00:08 areata on the life of patients and also involves the physical, psychological, social, emotional
00:13 and economic sphere.
00:14 This is why it is important to finally have an innovative, effective, safe and refundable
00:19 drug like Baricitinib.
00:20 It was discussed during the press conference organized by Lilia in Milan and entitled "Atopic
00:25 dermatitis and alopecia areata, two pathologies, one drug, free way to refundability".
00:30 In particular, patients who suffer from alopecia areata, an autoimmune disease that affects
00:36 about one person out of a thousand, had never had a drug of their own at their disposal.
00:43 To be able to give an answer today with an effective therapy and with a complete contribution
00:50 of the national health system is a huge victory for us and for our patients.
00:57 Contrary to the presence of eczema and itching, atopic dermatitis affects 8% of the Italian
01:03 adult population in the various degrees of severity.
01:06 The annoyance caused by the intense and constant itching can determine the impossibility of
01:10 spending peaceful nights of sleep over 5 days out of 7.
01:14 With the approval of the new drug, however, patients have a new hope.
01:18 We now have Baricitinib at our disposal, which is a drug refunded for the treatment of
01:27 severe moderate atopic dermatitis at the failure of a conventional therapy.
01:32 Already after the first intake, there is a reduction of itching in the first 3-4 hours.
01:37 People who suffer from severe moderate atopic dermatitis tend to isolate themselves, compromising
01:42 their quality of social and emotional life, but also their work life.
01:46 The possibility of having a support, a pharmacological help, but also social, also regarding work,
01:56 is very important for people who suffer from it.